In biliary tract cancer cell lines, Tazemetostat has been demonstrated to effectively reduce levels of H3K27me3 and upregulate the gene expression of fructose-bisphosphatase 1 (FBP1) (Bekric et al., 2023). This evidence concerns the gene FBP1 and biliary tract neoplasm.